Lowering blood pressure saves lives and primary care practice is where treatment for hypertension begins.

Resistant hypertension requires aggressive treatment with multiple drugs. Spironolactone is a key addition to the regimen.

Hypertension in hospitalized patients is best treated conservatively.

More about the current move away from beta-blocker therapy for hypertension as discussed by speakers at the 2013 ASH annual meeting. Following are some more of the key points, including a discussion of so-called beta-blockers "plus."

ASH 2013 has uncovered 2 glaring gaps in the management of people with sleep disorders (OSA as well as others) and appropriate care after a stroke. Both cohorts frequent primary care practice.

Patients with resistant hypertension and hypertensive patients prone to hyperkalemia are on the rise. They are not easy to care for, but certain “tricks of the trade” can help. Details here.

The meeting's goals are to increase understanding and, perhaps, find a cure.

A new study validates online delivery as an effective means of promoting dietary adherence in celiac disease, and this method may prove effective across diets for patients with obesity, metabolic syndrome, and diabetes.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

New drugs are needed because a significant fraction of patients reach the end of the line with existing therapies.

All patients with IBD should receive aggressive ongoing assessment of their inflammatory state and its response to immunomodulators, anti-TNF drugs, and other agents.

A purely dichotomous understanding of whether to start treatment for patients who have IBD with anti-TNF agents is becoming an outdated view.

Even the most experienced and skilled gastroenterologists in the country are struggling to make science-based decisions in this area.

These agents remain the mainstay of therapy for the majority of patients with the disease.

A straightforward discussion drove toward attendees toward the more current understanding of the clinical and genetic overlap between the 2 major forms of IBD.

Extraintestinal manifestations of inflammatory bowel disease affect the musculoskeletal, dermatologic, ocular, renal and pulmonary systems.

Therapy for ulcerative colitis and Crohn disease has been transformed with the introduction of anti–tumor necrosis factor treatment, according to University of Miami authors.

There are numerous treatment options, including a variety of over-the-counter agents to help patients with constipation. Here, a review of the more popular choices.

When to start screening-and which patients to screen? And with which screening method? Recommendations here from a panel of experts.

Patients with ulcerative colitis and Crohn’s disease typically don’t receive preventive services at the same rate as general medical patients. Vaccination is a key area of confusion.